Burzynski Research Institute: Metastatic Colon Cancer: In a Randomized Phase II Clinical Study, Antineoplaston Therapy Doubled the 5-Year Survival Rate Following Curative Resection of Hepatic Metastases
Published: May 27, 2009
HOUSTON--(BUSINESS WIRE)--The Burzynski Research Institute, Inc. (BRI) is pleased to announce the results of a randomized Phase II clinical study of antineoplaston therapy (ANP therapy) in metastatic colon cancer following curative resection of hepatic metastases. The study was performed at the Kurume University School of Medicine (Japan) in the Department of Surgery. A report of the study results is currently in press.